Profile: Target Discovery, Inc. develops and delivers products for oncology. Our Isonostic™ products offers a new class of biomarkers (protein isoforms) into clinical use, and our Isonostic™ assays are available to quantify both the isoforms currently seen by molecular diagnostics & a much wider variety of protein post translational modifications. Our molecular diagnostics offer insights into single nucleotide polymorphisms and splice variants, which account for 8 to 10 percent of protein isoforms.